Prof Birkmayer, MD, PHD is a world-renowned biochemical researcher and was the first to identify the importance of NADH in cellular development and energy transmission for ALL bodily functions and organs. He is the Medical Director of the Birkmayer Institute for Parkinson's Therapy in Vienna which has treated many thousands of patients suffering from Parkinson's disease, Alzheimer's disease and depression. He is the founder and Chairman of Birkmayer Pharmaceuticals and the Birkmayer Laboratories. Additionally, Prof Birkmayer is a professor at the University of Graz, Austria and head of its division of Neurochemistry at the Department of Medical Chemistry. He is also visiting professor at the University of Beijing and Canton, China and Secretary General of the International Academy of Tumor Marker Oncology in New York. Prof Dr Birkmayer is the European editor of The Journal of Tumor Marker Oncology and a member of the Journal of Experimental and Clinical Cancer Research.
Dr Walther Birkmayer (Prof Dr George Birkmayer's father) received four honorary doctorates for his ground breaking work on NADH and Sir John Eccles, the Nobel Laureate and chemist described the discovery of the benefits of CoEnzyme 1 as “more important than even the discovery of antibiotics”.
A stabilised form of NADH was developed by Prof Dr George Birkmayer.
The stabilised lozenge developed by Prof Birkmayer and his team is the only patented, stabilized, absorbable, oral form of NADH and is the result of decades of research and extensive toxicology and safety studies. Numerous studies have shown that it increases cellular production of ATP, the natural energy storage compound in the body.